← All trials
NCT04594135
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 30, 2020
- Primary completion
- Nov 30, 2022
- Completion date
- Nov 30, 2022
- First posted
- Oct 20, 2020
- Last posted
- Oct 20, 2020
- Enrollment
- 20
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- iCell Gene TherapeuticsLead sponsor
- Peking UniversityOverall official - principal investigator
- iCell Gene TherapeuticsCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.